Nanomedicine for Global Health

Journal of Laboratory Automation

Volumn 19, Issue 6, 2014, Pages 511-516

  Tsai, Nathaniel ^a   Lee, Bryan ^b   Kim, Austin ^a   Yang, Richard ^a   Pan, Ricky ^a   Lee, Dong Keun ^a   Chow, Edward K ^c,d   Ho, Dean ^a,b,e,f  

^a UCLA SCHOOL OF DENTISTRY   (United States)

^b Engineering IV   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cancer; drug delivery; global health; HIV AIDS; nanomedicine

Indexed keywords

DRUG DELIVERY; MEDICAL NANOTECHNOLOGY;

CANCER; GLOBAL HEALTH; GLOBAL POPULATION; HIV/AIDS; INFECTIOUS DISEASE; THIRD-WORLD COUNTRIES;

DISEASES;

DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORINATED PERFLUOROPOLYETHER; NANODIAMOND; NANOMATERIAL; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CANCER REGRESSION; CANCER THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOGENICITY; LIFE EXPECTANCY; MEDICAL TECHNOLOGY; NANOMEDICINE; NANOTECHNOLOGY; PARTICLE REPLICATION IN NON WETTING TEMPLATE TECHNIQUE; PUBLIC HEALTH; REVIEW; DIAGNOSTIC TEST; HEALTH; PROCEDURES; THERAPY; TRENDS;

DIAGNOSTIC TESTS, ROUTINE; GLOBAL HEALTH; HUMANS; NANOMEDICINE; THERAPEUTICS;

EID: 84911921184     PISSN: 22110682     EISSN: 22110690     Source Type: Journal    
DOI: 10.1177/2211068214538263     Document Type: Review

References (45)

1. World Health Statistics 2013. Geneva, Switzerland: World Health Organization; 2013:
2. Noncommunicable Diseases Fact Sheet. Geneva, Switzerland: World Health Organization; 2013:
3. Singer P. A.,Taylor A. D.,Daar A. S., et al.Grand Challenges in Global Health: The Ethical, Social and Cultural Program.PLoS Med. 2007;4:1440-1444
4. Grand Challenges in Global Health. Challenge 1: Create Effective Single Dose Vaccines That Can Be Used Soon after Birth. In: Grand Challenges in Global Health, 2013. http://www.grandchallenges.org/ImproveVaccines/Challenges/SingleDose/Pages/default.aspx.
5. Charrois G. J. R.,Allen T. M.Drug Release Rate Influences the Pharmacokinetics, Biodistribution, Therapeutic Activity, and Toxicity of Pegylated Liposomal Doxorubicin Formulations in Murine Breast Cancer.Biochim. Biophys. Acta. 2004;1663:167-177
6. Siepmann J.,Faisant N.,Akiki J., et al.Effect of the Size of Biodegradable Microparticles on Drug Release: Experiment and Theory.J. Control. Release. 2004;96:123-134
7. Partridge A. H.,Burstein H. J.,Winer E. P.Side Effects of Chemotherapy and Combined Chemohormonal Therapy in Women with Early-Stage Breast Cancer.J. Natl. Cancer Inst. Monogr. 2001;30:135-142
8. Webster T. J.Nanomedicine: What’s in a Definition?.Int. J. Nanomed. 2006;1:115-116
9. Mirkin C. A.,Nel A.,Thaxton C. S.Applications: Nanobiosystems, Medicine, and Health.Nanotechnology Research Directions for Societal Needs in 2020. 2011;1:305-374
10. Moghimi S. M.,Hunter A. C.,Murray J. C.Nanomedicine: Current Status and Future Prospects.FASEB J. 2005;19:311-330
11. Khademhosseini A.,Peppas N. A.Micro- and Nanoengineering of Biomaterials for Healthcare Applications.Adv. Healthc. Mater. 2013;2:10-12
12. Boisseau P.,Loubaton B.Nanomedicine, Nanotechnology in Medicine.Comptes Rendus Physique. 2011;12:620-636
13. Creixell M.,Peppas N. A.Co-Delivery of siRNA and Therapeutic Agents Using Nanocarriers to Overcome Cancer Resistance.SciVerse ScienceDirect. 2012;7:367-379
14. Whitesides G. M.The ‘Right’ Size in Nanobiotechnology.Nat. Biotechnol. 2003;21:1161-1165
15. Farokhzad O. C.,Langer R.Impact of Nanotechnology on Drug Delivery.ACS Nano. 2009;3:16-20
16. Nanomedicine, 2005. http://www.esf.org/publications/forward-looks.html. Accessed on March 18, 2014.
17. Adiseshaiah P. P.,Hall J. B.,McNeil S. E.Nanomaterial Standards for Efficacy and Toxicity Assessment.Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2009;2:99-112
18. du Toit L. C.,Pillay V.,Choonara Y. E.Nano-Microbicides: Challenges in Drug Delivery, Patient Ethics and Intellectual Property in the War against HIV/AIDS.Adv. Drug Deliv. 2010;62:532-546
19. Jensen S. A.,Day E. S.,Ko C. H., et al.Spherical Nucleic Acid Nanoparticle Conjugates as an RNAi-Based Therapy for Glioblastoma.Sci. Transl. Med. 2013;5:209ra152
20. Hay Burgess D. C.,Wasserman J.,Dahl C. A.Global Health Diagnostics.Nature. 2006;444:1-2
21. Morton S. W.,Herlihy K. P.,Shopsowitz K. E., et al.Scalable Manuface of Built-to-Order Nanomedicine: Spray-Assisted Layer-by-Layer Functionalization of PRINT Nanoparticles.Adv. Mater. 2013;25:4707-4713
22. Valencia P. M.,Farokhzad O. C.,Karnik R., et al.Microfluidic Technologies for Accelerating the Clinical Translation of Nanoparticles.Nat. Nanotechnol. 2012;7:623-629
23. Desimone J. M.,Wang J.-Y.,Wang Y.Three-Dimensional Nanoarchitectures: Designing Next-Generation Devices. Springer Science+Business Media: New York; 2011:90-107.
24. Gratton S. E. A.,Ropp P. A.,Pohlhaus P. D., et al.The Effect of Particle Design on Cellular Internalization Pathways.Proc. Natl. Acad. Sci. U.S.A. 2008;105:11613-11618
25. Galloway A. L.,Murphy A.,DeSimone J. M., et al.Development of a Nanoparticle-Based Influenza Vaccine Using the PRINT® Technology.Nanomed. Nanotechnol. Biol. Med. 2013;9:523-531
26. Kaplan L. D.HIV-Associated Lymphoma.Best Pract. Res. Clin. Haematol. 2012;25:101-117
27. Gupta U.,Jain N. K.Non-Polymeric Nano-Carriers in HIV/AIDS Drug Delivery and Targeting.Adv. Drug Deliv. Rev. 2010;62:478-490
28. Elechiguerra J. L.,Burt J. L.,Morones J. R., et al.Interaction of Silver Nanoparticles with HIV-1.J. Nanobiotechnol. 2005;3:1-10
29. Cancer Facts & Figures 2014. American Cancer Society: Los Angeles; 2014:
30. Kawasaki E. S.,Player A.Nanotechnology, Nanomedicine, and the Development of New, Effective Therapies for Cancer.Nanomed. Nanotechnol. Biol. Med. 2005;1:101-109
31. He Q.,Gao Y.,Zhang L., et al.One-Pot Self-Assembly of Mesoporous Silica Nanoparticle-Based pH-Responsive Anti-Cancer Nano Drug Delivery System.J. Mater. Chem. 2011;21:15190-15192
32. Abdullah L. N.,Chow E. K.-H.Mechanisms of Chemoresistance in Cancer Stem Cells.Clin. Transl. Med. 2013;2:1-9
33. Park J. H.,Lee S.,Kim J.-H., et al.Polymeric Nanomedicine for Cancer Therapy.Prog. Polymer Sci. 2008;33:113-137
34. Shapira A.,Livney Y. D.,Broxterman H. J., et al.Nanomedicine for Targeted Cancer Therapy: Towards the Overcoming of Drug Resistance.Drug Resist. Updates. 2011;14:150-163
35. Chow E. K.-H.,Ho D.Cancer Nanomedicine: From Drug Delivery to Imaging.Sci. Transl. Med. 2013;5:216rv4
36. Zhang L.,Gu F. X.,Chan J. M., et al.Nanoparticles in Medicine: Therapeutic Applications and Developments.Clin. Pharmacol. Ther. 2008;83:761-769
37. Gao Z.,Kennedy A. M.,Christensen D. A., et al.Drug-Loaded Nano/Microbubbles for Combining Ultrasonography and Targeted Chemotherapy.Ultrasonics. 2008;48:260-270
38. Lal S.,Clare S. E.,Halas N. J.Nanoshell-Enabled Photothermal Cancer Therapy: Impending Clinical Impact.Accounts Chem. Res. 2008;41:1842-1851
39. Dickerson E. B.,Dreaden E. C.,Huang X., et al.Gold Nanoroad Assisted Near-Infrared Plasmonic Photothermal Therapy (PPTT) of Squamous Cell Carcinoma in Mice.Cancer Lett. 2008;269:57-66
40. Man H. B.,Zhang K.,Robinson E., et alUltrananocrystalline Diamond: Synthesis, Properties, and Applications. Kidlington, UK: William Andrew; 2012:493-517.
41. Chow E. K.,Zhang X.-Q.,Chen M., et al.Nanodiamond Therapeutic Delivery Agents Mediate Enhanced Chemoresistant Tumor Treatment.Sci. Transl. Med. 2011;3:73ra21
42. Moore L.,Chow E. K.-H.,Osawa E., et al.Diamond-Lipid Hybrids Enhance Chemotherapeutic Tolerance and Mediate Tumor Regression.Adv. Mater. 2013;25:3532-3541
43. Mochalin V. N.,Shenderova O.,Ho D., et al.The Properties and Applications of Nanodiamonds.Nat. Nanotechnol. 2012;7:11-23
44. Hrkach J. H.,Hoff D. V.,Ali M. M., et al.Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile.Sci. Transl. Med. 2012;4:1-11
45. Miele E.,Spinelli G. P.,Miele E., et al.Albumin-Bound Formulation of Paclitaxel (Abraxane® ABI-007) in the Treatment of Breast Cancer.Int. J. Nanomed. 2009;4:99-105